SIGHT SCIENCES INC (SGHT) Stock News
NASDAQ:SGHT - Nasdaq - US82657M1053 - Common Stock - Currency: USD
SGHT Latest News, Press Relases and Analysis
Sight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Sight Sciences (SGHT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
Sight Sciences (SGHT) delivered earnings and revenue surprises of 3.45% and 5.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CLPT
Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and...
Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance
Artivion (AORT) Lags Q1 Earnings Estimates
Artivion (AORT) delivered earnings and revenue surprises of -50% and 4.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: AORT
Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025
MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology...
Sight Sciences Appoints Gary Burbach to its Board of Directors
MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology...
Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio
New system features higher viscoelastic capacity and TruSync™ technology, engineered to safely synchronize surgical control and precision in implant-free,...
Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th
MENLO PARK, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology...
Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance
MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (
SGHT Stock Earnings: Sight Sciences Misses EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sight Sciences (NASDAQ:SGHT) just reported results for the first quarter of 202...
Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting
A Meta-Analysis of 22 Studies, and Data from the IRIS® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates Significant,...
Sight Sciences to Present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology...
Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options
Budget impact analysis published in the Expert Review of Ophthalmology journal...
Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference
MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (
Sight Sciences to Report Third Quarter Financial Results on November 7, 2024
MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology...
Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial
The study found improvements in reading speed, vision-related quality of life, and suggested potential benefits of an interventional approach for patients...
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
MENLO PARK, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024
MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology...
Sight Sciences Announces the Release of its First Sustainability Report
The Sustainability Report provides data for 2021 through 2023 on the Company’s environmental, social, and governance initiatives...
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the...
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma
The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma as...
SGHT Stock Earnings: Sight Sciences Misses EPS, Beats Revenue for Q1 2024
SGHT stock results show that Sight Sciences missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on...
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology...
Sight Sciences gibt die Veröffentlichung einer groß angelegten, praxisnahen MIGS-Studie als Nachweis für die Wirksamkeit des umfassenden Verfahrens zur Wiederherstellung des Kammerwasserabflusses mit der OMNI® Surgical System-Technologie sowohl bei der
Die Wirksamkeit der drei am häufigsten verwendeten MIGS-Technologien in Kombination mit einer Kataraktoperation und der Kataraktoperation allein wurde an...